NCT04575467View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

November 15, 2021

Study Completion Date

December 8, 2021

Conditions
Subcutaneous Fat
Interventions
DRUG

CBL-514

CBL-514 will be administered via injection into the subcutaneous adipose layer.

Trial Locations (1)

Unknown

Investigational Site, Melbourne

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT04575467 - A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) | Biotech Hunter | Biotech Hunter